Not known Facts About YX-2-107
MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To judge many intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Most important trial aims were to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyositis peo